AbbVie and Boehringer Ingelheim Resolve HUMIRA® U.S. Patent Litigation

| By | AbbVie, Boehringer Ingelheim, Drug Patents
0
128

AbbVie announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant Boehringer Ingelheim a non-exclusive license to its HUMIRA-related intellectual property in the United States.

The U.S. license for BI will begin on July 1, 2023.  BI will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity and enforceability of the licensed patents. AbbVie will make no payments of any form to BI.

“This is an important settlement as it resolves all HUMIRA-related patent litigation in the U.S and provides access for another biosimilar manufacturer seeking to enter the U.S.,”

said Laura Schumacher, Vice Chairman, External Affairs and Chief Legal Officer at AbbVie.

“As an innovation-driven biopharmaceutical company, we will continue to develop novel cures for the toughest health challenges and rely on a robust patent system to protect that investment in innovation.”

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

SOURCE: abbvie.com
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.